As there exists two distinct populations of CSCs in breast cancer, when reviewing the literature for the potential role of prostaglandin signaling in breast CSC phenotypes it is important to define how the CSCs were identified since there may be a CD44+/CD24- or ALDH+ specific effect. This evidence concerns the gene CD24 and breast carcinoma.